[PDF] Clinical Pearls in Anesthesia for Xeroderma Pigmentosum: A Case





Previous PDF Next PDF



Clinical Pearls in Anesthesia for Xeroderma Pigmentosum: A Case

Abstract: Xeroderma Pigmentosum (XP) is a rare autosomal recessive (AR) disease characterized by hypersensitivity of the skin to ultra violet (UV) radiation 



XERODERMA PIGMENTOSUM: A HUMAN DISEASE IN WHICH AN

Skin fibroblasts from patients with homozygous xeroderma pigmentosum show reduced amounts of DNA repair replication in vitro.6 Repair replication which.



Xeroderma pigmentosum â•? bridging a gap between clinic and

Xeroderma pigmentosum (XP) is an autosomal reces- sive photosensitive disorder with an extremely high in- cidence of UV-related skin cancers associated with.



Characterization of a splicing mutation in group A xeroderma

Xeroderma pigmentosum (XP) is an autosomal recessive human genetic disorder manifested as extreme sensitivity to sunlight resulting in a very high incidence 



Xeroderma pigmentosum and acute myeloid leukemia: a rare

Abstract. Background: Xeroderma pigmentosum is a rare inherited disease characterized by extreme hypersensitivity to ultraviolet rays and predisposing to 



Xeroderma Pigmentosum: Gene Variants and Splice Variants

Jul 29 2021 Alterations in genes of the NER can lead to DNA damage repair disorders such as Xeroderma pigmentosum (XP). XP is a rare autosomal recessive ...



Neurological symptoms and natural course of xeroderma

Xeroderma pigmentosum (XP) is a rare autosomal recessive disease with cutaneous ocular and neurological symptoms. The basic defect is in DNA repair.



Living with xeroderma pigmentosum: comprehensive

Xeroderma pigmentosum (XP) is a rare autosomal recessive disease of deoxyribonucleic acid (DNA) repair with ultraviolet (UV) radiation sensitivity.



xeroderma-pigmentosum.pdf

May 1 2010 Xeroderma pigmentosum is caused by mutations in genes that are involved in repairing damaged DNA. DNA can be damaged by UV rays from the sun and ...



Oculocutaneous manifestations in xeroderma pigmentosa

Xeroderma pigmentosum (XP) is a rare genetic disease characterised by defective DNA repair leading to clinical and cellular hypersensitivity.



[PDF] Le xeroderma pigmentosum - Orphanet

Le xeroderma pigmentosum (XP) est une maladie génétique héréditaire rare www orpha net/data/patho/Pub/fr/XerodermaPigmentosum-FRfrPub3253v01 pdf Juin 



[PDF] Xeroderma Pigmentosum - Argumentaire - Haute Autorité de Santé

13 sept 2021 · Le Xeroderma Pigmentosum (XP) correspond à un groupe de maladies rares transmises sur le mode autosomique récessif caractérisées par une 



[PDF] Xeroderma Pigmentosum - Haute Autorité de Santé

13 sept 2021 · Le Xeroderma Pigmentosum (XP) correspond à un groupe de maladies rares transmises sur le mode autosomique récessif caractérisées par une 



Xeroderma pigmentosum - EM consulte

Le xeroderma pigmentosum (XP) est une génodermatose qui se manifeste par des altérations cutané-oculaires photo-induites et des cancers cutanés



[PDF] Le Syndrome Xeroderma Pigmentosum-C - Thesesfr

Au laboratoire nous nous intéressons à la pathologie Xeroderma Pigmentosum (XP) XP est une maladie génétique récessive autosomique rare



[PDF] Xeroderma pigmentosum - Université Cadi Ayyad

30 déc 2019 · Xeroderma pigmentosum : aspects épidémiologique clinique et thérapeutique Au service de chirurgie plastique CHU Med VI –Marrakech



[PDF] LES ASPECTS GENETIQUES ET CLINIQUES DE XERODERMA

1 mar 2022 · Les aspects génétiques et cliniques de Xeroderma Pigmentosum Thèse N°078/22 10/fimarad_pnd_xp_argumentaire_v3_29092021 pdf



[PDF] Le xeroderma pigmentosum et ses manifestations oculaires - Serval

10 avr 2014 · Le xeroderma pigmentosum (XP) est une maladie génétique rare trans- mise sur le mode autosomique récessif et caractérisée cliniquement par une 



[PDF] Xeroderma pigmentosum - MedlinePlus

3 avr 2023 · Xeroderma pigmentosum commonly known as XP is an inherited condition characterized by an extreme sensitivity to ultraviolet (UV) rays from 

  • Quels sont les causes du xeroderma pigmentosum ?

    Le xeroderma pigmentosum est une maladie génétique rare liée le plus souvent à une mutation sur le gène codant la protéine XPC. Le rôle de cette protéine est de reconnaître les lésions de l'ADN provoquées par les ultraviolets de la lumière naturelle.
  • C'est quoi le xeroderma pigmentosum ?

    Le Xeroderma Pigmentosum (XP) correspond à un groupe de maladies rares, transmises sur le mode autosomique récessif, caractérisées par une extrême sensibilité au rayonnement ultra-violet (UV) en particulier UVB (1). Le XP appartient au groupe des maladies qui prédisposent au cancer.13 sept. 2021
  • Le XP se transmet de manière autosomique récessive, ce qui signifie que les personnes atteintes sont porteuses du gène défectueux (muté) en deux exemplaires (l'un transmis par le père, l'autre par la mère). Les parents, eux, ne sont pas malades puisqu'ils ne portent qu'un exemplaire du gène muté (figure 2).
Send Orders for Reprints to reprints@benthamscience.ae

36 The Open Anesthesiology Journal, 2015, 9, 36-38

1874-3218/15 2015 Bentham Open

Open Access

Clinical Pearls in Anesthesia for Xeroderma Pigmentosum: A Case Report S.B. Shah*, U. Hariharan, B.K. Naithani and A.K. Bhargava Rajiv Gandhi Cancer Institute and Research Centre; Sec-5; Rohini, Delhi-110085, India

Abstract: Xeroderma Pigmentosum (XP) is a rare autosomal recessive (AR) disease characterized by hypersensitivity of

the skin to ultra violet (UV) radiation, resulting in a high frequency of UV induced skin tumors and progressive neuro-

logical complications at an early age. Through the following case report we emphasize that perioperative management of

xeroderma patients entails meticulous evaluation for neurological abnormalities, shielding the skin from OT (operation

theatre) lights by using protective clothing, sunscreen and UV blocking film as well as avoidance of genotoxic drugs like

volatile anaesthetics and paracetamol. One must be prepared for the possibility of difficult mask ventilation (we used a

mask one size larger), difficult intubation and prolonged effect of muscle relaxants (as in our case) due to skin atrophy,

neoplasia, joint contracture and neuronal dysfunction. Keywords: Basal cell carcinoma, genotoxic drugs, muscle relaxants, ultraviolet light, volatile anaesthetics, xeroderma pigmen-

tosum.

INTRODUCTION

The prevalence of Xeroderma Pigmentosa (XP) is

1:250,000 globally. Here, the ability to repair damage caused

by ultraviolet (UV) rays is deficient due to Nucleotide Exci- sion Repair (NER) damage [1, 2]. XP patients (colloquially called "children of the night") have a 1000-fold increased risk of developing neoplasias on sun exposed areas. Multiple basal cell carcinomas are frequent. Metastatic malignant melanoma and squamous cell carcinoma are common causes of death [3, 4]. We present a patient of xeroderma pigmen- tosa who was posted for basal cell neoplasm (BCC) excision of the nose. Initially she presented for excision of BCC on right ala of nose and six months later, for excision of BCC on her left nostril.

CASE REPORT

A 12 year old, 27Kg female, presented with mottled blackish pigmentation over sun exposed areas of her skin. She was diagnosed with a growth (size 6cmx4cmx3cm) pro- truding out of the right nasal cavity since the past one month, accompanied by nasal bleeding. There was intense lacryma- tion from her eyes and the conjunctiva was chemosed. The family history was positive, with her younger sister also suf- fering from xeroderma pigmentosa. A detailed preanaesthetic evaluation was done as per routine, with special attention to protecting her exposed parts. In the ward, an IV access was obtained gently. A non- abrasive, hypoallergenic UV blocking sunscreen (Sun Pro- tection Factor: 40) was applied on all the exposed areas of her skin followed by draping with protective clothing. Intra- venous 0.5mg midazolam was injected as premedication. In the OT, the patient was preoxygenated with 100% oxygen using a face mask one size larger than what would normally *Address correspondence to this author at the Rajiv Gandhi Cancer Institute and Research Centre; sec-5; Rohini, Delhi-110085, India; Tel: 9891769779;

E-mail: drshagun_2010@rediffmail.com

fit her face (to accommodate the tumor) and a sterile gauze with paraffin tulle on one side was placed on her lesion prior to masking to avoid trauma. Anaesthesia was induced using fentanyl 40g IV followed by propofol 55mg IV. Succinyl- choline was used in a dose of 40mg IV and a six mm ID en- dotracheal tube (ETT) was orally inserted into the trachea and ETT position confirmed by auscultation and capnogra- phy. Antibiotic eye ointment was applied before patching and padding her eyes. Her face, neck and extremities were covered with cotton before switching the OT lights on. Total intravenous anaesthesia (TIVA) was utilized using a propo- fol infusion (4mg/ml at 10-15 ml/hour) and two intermittent fentanyl boluses of 5g each. Besides routine monitoring, bispectral index (BIS) and neuromuscular monitoring were used. The effect of succinylcholine lasted 24 minutes which also happened to be the surgical time. Extubation was un- eventful. Postoperative analgesia with IV diclofenac and tramadol both 25 mg 8 hourly was given. The same patient presented six months later, with an ul- cerated left nostril growth. This time again, BIS- guided TIVA with propofol and fentanyl for anaesthesia was utilised (Fig. 1). As the duration of action of succinylcholine was prolonged in the previous instance, this time two smaller doses of succinylcholine (25mg I.V) 10 minutes apart was administered. The rest of the perioperative course was un- eventful. The same precautions and monitoring were utilized in this surgery as was done in the first time. Postoperatively also, special care was taken to protect and cover her exposed areas.

DISCUSSION

Xeroderma Pigmentosum (XP) is a rare genetic disorder affecting the skin and the nervous system. At birth, the skin appears normal. Onsetting at around 6 months, XP pro- gresses to stage-1 with sun exposed areas showing erythema and freckling. Continuous sun- exposure leads to stage-2 XP, presenting with poikiloderma, solar lentigines, skin atrophy,

Clinical Pearls in Anesthesia for Xeroderma Pigmentosum The Open Anesthesiology Journal, 2015, Volume 9 37

Fig. (1). Intra operative image of xeroderma pigmentosa patient. telangiectasias, patches of hypopigmentation and hyperpig- mentation. Stage-3 involves development of actinic kerato- ses and skin cancer occurring anywhere between 4-5 years of age to adolescence [3, 4].

Neurological abnormalities include loss of high-

frequency hearing (commonest), poor co-ordination, hypore- flexia, progressive mental retardation, seizures and spastic- ity, [5] all of which may worsen with the use of volatile an- aesthetic agents [1, 2, 6].

Ocular symptoms include photo-

phobia, conjunctivitis, loss of vision, irritation, blepharitis, keratitis and ocular neoplasia. Hypersensitivity to environmental mutagens (cigarette smoke and alcohol) exists. Perioperative management entails meticulous evaluation of airway, neurological abnormalities, shielding the skin from OT lights by using protective cloth- ing, ultraviolet (UV) blocking film [7, 8] and avoidance of drugs like paracetamol, halothane, isoflurane and sevoflu- rane which are known to derange Nucleotide Excision Re- pair (NER) [1, 2, 9]. Comet assay [10, 11] (alkaline single cell gel electrophoresis) demonstrates peripheral blood lym- phocyte DNA damage at 60 mins and at 120 mins of anaes- thesia with 1 to 1.5% halothane, isoflurane and sevoflurane. The anesthetics-induced DNA strand breaks as well as al- kali-labile sites are measured as total comet length (i.e., in- crease of a DNA migration). Volatile anaesthetics increase DNA migration in a dose-dependent manner. Halothane in- creases DNA migration to a higher extent than isoflurane. The comet assay detects DNA strand breaks induced directly by genotoxic agents as well as DNA degradation due to cell death. Increase of DNA migration induced in PBL by isoflu- rane at 1 mM and by halothane at 0.1 mM is caused by their genotoxic action. This is repaired by the 5 th post-operative day in normal patients, but in XP patients, it leads to pro- gression of neurological symptoms [10]. Therefore we pre- ferred TIVA (total intravenous anaesthesia) to volatile anaes-

thetic usage. There is also increased sensitivity to synergistic effects of benzodiazepines and opioids due to immature

brain development. Hence, we used lower end of the dose range for midazolam, morphine and fentanyl [6]. All preparations for difficult airway were done preopera- tively. Possibility of difficult masking, difficult intubation and prolonged effect of muscle relaxation due to skin atro- phy, neoplasia, joint contracture and neuronal dysfunction exists. Hence, we used a short- acting neuromuscular blocker (succinylcholine) to facilitate tracheal intubation. Succinyl- choline effect was prolonged in the first surgery, probably due to deficiency in pseudo cholinesterase levels and hence, we reduced the dose during second surgery.

CONCLUSION

Eliciting a family history, detailed neurological evalua- tion, prior counselling regarding strict avoidance of sun, cigarette smoking and alcohol to delay disease progression and stressing the importance of sun- protective clothing, eye gear, sunblock creams cannot be over-emphasized. We ad- vocate avoidance of genotoxic drugs like halothane, isoflu- rane, sevoflurane and paracetamol due to derangement in NER. We recommend opting for BIS guided TIVA for gen- eral anaesthesia, cautious use of opioids and benzodiazepines and utilizing shorter acting neuromuscular blocking agents under strict PNS (peripheral nerve stimulator) guidance. Gentle handling of the patient during all manoeuvres and special care of their fragile skin is very important.

CONFLICT OF INTEREST

The authors confirm that this article content has no con- flict of interest.

ACKNOWLEDGEMENTS

Declared none.

38 The Open Anesthesiology Journal, 2015, Volume 9 Shah et al.

REFERENCES

[1] Miyazaki R, Nagata T, Kai T, Takahashi S. Anaesthesia for a pa- tient with xeroderma pigmentosum. Masui 2007; 56(4): 439-41. [2] Masuda Y, Imaizumi H, Okanuma M, Narimatsu E, Asai Y, Namiki A. Anaesthesia for a patient with xeroderma pigmentosum

Masui 2002; 51(2): 169-71.

[3] Lichon V. Xeroderma Pigmentosum: beyond skin cancer. J Drugs

Dermatol 2007; 6: 281-8.

[4] Kraemer KH, Patronas NJ, Schiffmann R, Brooks BP, Tamura D, DiGiovanna JJ. Xeroderma Pigmentosum, Trichothiodystrophy and Cockrayne syndrome: a complex genotype-phenotype relationship.

Neuroscience 2007; 145: 1388-96.

[5] Anttinen A, Koulu L, Nikoskelainen E, et al. Neurological symp- toms and natural course of xeroderma pigmentosum. Brain 2008;

131(8): 1979-89.

[6] Shrestha GS, Shah RP, Amatya AG, Shrestha N. Anaesthetic man- agement of patients with Xeroderma pigmentosum. A series of

three cases. Nepal Med Coll J 2011; 13(3): 231-2. [7] Soen M, Kagawa T, Uokawa R, Suzuki T. Anaesthetic manage-

ment of a patient with xeroderma pigmentosum. Masui 2006;

55(2): 215-7.

[8] Tatsuo O, Takashi I. Anaesthesia for a Patient with Xeroderma

Pigmentosum. J Clin Anaesth 2005; 29(5): 909-10.

xeroderma pigmentosum. Pediatric Anaesthesia 2004; 14(8): 621- 712.
[10] Karabiyik L, Sarda S, Polat U, KocabaS NA, Karakaya AE. Com- parison of genotoxicity of sevoflurane and isoflurane in human lymphocytes studied in vivo using the comet assay. Mutat Res

2001; 492(1): 99-107.

[11] Jaloszyski P, Kujawski M, Wasowicz M, Szulc R, Szyfter K. Genotoxicity of inhalation anaesthetics halothane and isoflurane in human lymphocytes studied in vitro using the comet assay. Mutat

Res 1999; 439(2): 199-206.

Received: December 06, 2014 Revised: March 25, 2015 Accepted: November 03, 2015

© Shah et al.; Licensee Bentham Open.

This is an open access article licensed under the terms of the (https://creativecommons.org/licenses/by/4.0/legalcode), which permits unrestricted, non-

commercial use, distribution and reproduction in any medium, provided the work is properly cited.quotesdbs_dbs43.pdfusesText_43
[PDF] cartographie des risques stratégiques

[PDF] gestion des risques danone

[PDF] risques environnementaux définition

[PDF] recombinaison non homologue

[PDF] types de risques environnementaux pdf

[PDF] recombinaison site spécifique

[PDF] recombinaison homologue plasmide

[PDF] prévention et gestion des risques environnementaux

[PDF] évaluation des risques environnementaux

[PDF] réglage chasse d'eau

[PDF] comment gérer les risques financiers

[PDF] gestion des risques financiers dans une banque

[PDF] analyse des risques financiers

[PDF] les différents risques financiers pdf

[PDF] erreur philosophie